The Global Biologics CDMO Market is expected to witness a growth rate of 14-16% in the next five years. Growing ...

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

The US Food and Drug Administration (FDA) has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal ... biologics licence applications (BLA) for the antibody.

AI-based computational models are expected to play a larger role in drug development. Animal testing requirements for monoclonal antibodies ... about many full biological systems.

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal ...

The initiatives reflect the latest measures from federal agencies to reduce and ultimately replace animal testing in drug development and ...

The potential of monoclonal antibodies (mAbs ... AI/ML models last year. AI-biologics vs. AI-small molecule discovery spaces Compared to the small molecule AI drug discovery ecosystem, this ...

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous ...

The Large Molecule Bioanalytical Technologies Market is expected to grow from USD 9.29 Billion in 2024 to USD 16.76 Billion ...

Innovent Biologics, Inc., a biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune ...